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Abstract
Background: Influenza surveillance helps time prevention and control interventions 
especially where complex seasonal patterns exist. We assessed influenza surveillance 
sustainability in Africa where influenza activity varies and external funds for surveil-
lance have decreased.
Methods: We surveyed African Network for Influenza Surveillance and Epidemiology 
(ANISE) countries about 2011-2017 surveillance system characteristics. Data were 
summarized with descriptive statistics and analyzed with univariate and multivariable 
analyses to quantify sustained or expanded influenza surveillance capacity in Africa.
Results: Eighteen (75%) of 24 ANISE members participated in the survey; their cu-
mulative population of 710 751 471 represent 56% of Africa's total population. All 
18 countries scored a mean 95% on WHO laboratory quality assurance panels. The 
number of samples collected from severe acute respiratory infection case-patients 
remained consistent between 2011 and 2017 (13 823 vs 13 674 respectively) but de-
creased by 12% for influenza-like illness case-patients (16 210 vs 14 477). Nine (50%) 
gained capacity to lineage-type influenza B. The number of countries reporting each 
week to WHO FluNet increased from 15 (83%) in 2011 to 17 (94%) in 2017.
Conclusions: Despite declines in external surveillance funding, ANISE countries 
gained additional laboratory testing capacity and continued influenza testing and re-
porting to WHO. These gains represent important achievements toward sustainable 
surveillance and epidemic/pandemic preparedness.
K E Y W O R D S
Africa, ANISE, capacity, influenza, surveillance
1  | INTRODUC TION
Although sentinel surveillance in African countries for viral respi-
ratory infections such as influenza is important for prevention and 
control, funding for such activities has steadily decreased making 
its sustainability uncertain. Africa has a higher influenza-associated 
mortality burden than other regions. This is important as few African 
countries routinely vaccinate against influenza and or treat severe 
respiratory illnesses empirically with antivirals during the influenza 
seasons.1,2 Much of Africa's population is low and middle income and 
have substantial prevalence of underlying medical conditions3-5 and 
limited access to health care, increasing the risk of severe compli-
cations as a result of influenza illness.6 Only 3 of Africa's 54 coun-
tries have government-subsidized seasonal influenza vaccination 
programs.7 Nevertheless, more African countries have influenza 
vaccines available through the private sector, are evaluating the po-
tential value of influenza vaccination,8-10 or are introducing publicly 
available influenza vaccines among key risk groups. In addition to na-
scent influenza vaccination programs, some countries in Africa also 
treat severe influenza illnesses during influenza epidemics and pan-
demics with empiric antivirals, and/or deploy non-pharmaceutical 
interventions to prevent contagion during epidemics (eg, respiratory 
hygiene, social distancing, and hand washing campaigns).5,11-13 The 
impact of these interventions is optimized by their timely deploy-
ment immediately before the anticipated start of epidemics.
Given the value of influenza surveillance for seasonal epidemic 
and pandemic mitigation, international agencies and governments 
provided substantial financial and technical resources to build 
global influenza surveillance capacity at the turn of the century.14 
Much investment in capacity-building in the early 2000s occurred 
in Africa which had a dearth of surveillance and a disproportionate 
disease burden. As a result, influenza surveillance rapidly improved 
throughout Africa during the peri-pandemic period. The strength-
ening of surveillance allowed countries to better define their ep-
idemic periods and, as a secondary benefit, estimate the burden 
of respiratory illnesses attributable to influenza.15-21 Investments 
were higher during the initial years of grants to encourage rapid 
capacity-building and operationalization of surveillance, resources 
     |  3IGBOH et al.
then tapered off with countries assuming greater technical and 
financial responsibility of their systems. For example, the US 
Centers for Disease Control and Prevention (CDC) funding to 15 
African nations, through cooperative agreements, peaked during 
2006 and decreased by approximately 50% in the subsequent 
decade.
The rapid investment and gradual divestiture strategy rapidly 
built sustainable influenza surveillance capacity in the Americas,14 
but it is unclear if this strategy has also been effective in Africa. 
The African Network for Influenza Surveillance and Epidemiology 
(ANISE) is a regional consortium of subject matter experts seeking to 
improve surveillance in Africa. Most African countries who are mem-
bers of ANISE have previously used their influenza-like illness (ILI) 
and/or severe acute respiratory infection (SARI) or other respiratory 
disease surveillance systems to identify and test for the Middle East 
respiratory syndrome (MERS)22 and severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2). Indeed, these platforms have 
been critical to the 2019 coronavirus disease (COVID-19) pandemic 
response in Africa.23,24 Given the importance of these platforms, we 
sought to evaluate influenza sentinel surveillance function in Africa 
from 2011 to 2017,5 after external funding to surveillance in Africa 
started to decrease and determine if initial investments in capaci-
ty-building led to sustainable influenza surveillance.
2  | METHODS
2.1 | Study population
During the sixth ANISE25 meeting in Antananarivo, Madagascar in 
2018, we invited ANISE member states to participate in Influenza 
Surveillance in Africa (InSAFRO), a survey to assess surveillance 
systems in Africa and their participation in the World Health 
Organization's (WHO) Global Influenza Surveillance and Response 
System (GISRS). ANISE is a network of laboratorians, epidemiolo-
gists, public health officials, physicians, veterinarians, researchers 
and policy makers who collaborate to strengthen capacity for respir-
atory virus surveillance and research in Africa. ANISE promotes the 
use of standardized protocols for surveillance of respiratory illnesses 
to generate evidence for public health interventions and policy.
2.2 | Data collection
We used a standardized survey to gather information about sentinel 
surveillance practices, real-time reverse transcription polymerase 
chain reaction (rRT-PCR) capacity, the number of samples tested, 
and the number positive for influenza by week and age group during 
2011-2017. Influenza type, subtype, and lineage data were collected, 
if available. To explore whether influenza surveillance networks had 
expanded or contracted during the study period, we also gathered 
information about the type of surveillance conducted (ie, for ILI and/
or SARI), and number of active sites. We assessed whether the case 
definitions reported by the survey matched WHO-recommended 
ILI and SARI case definitions.26 Data were collected through the 
InSAFRO survey about national surveillance operational costs and 
funding sources. We reviewed reported avenues for regular dis-
semination of surveillance data in country to determine whether the 
generated influenza surveillance data were used to inform influenza 
prevention and control measures (eg, launching risk communication 
and vaccination campaigns). Finally, we surveyed participants about 
national vaccine policies or guidelines that could benefit from influ-
enza surveillance.
2.3 | Additional data collection
We also gathered information about influenza test results reported 
to the GISRS platform FluNet [40] and about samples shared with 
WHO Collaborating Centers (CCs). We reviewed published and un-
published burden of disease estimates solely to estimate the number 
from InSAFRO countries (ie, not to extract findings for a meta-anal-
ysis); this review was conducted until September 2019. We summa-
rized findings by World Bank income classification and population 
size27 to estimate the representativeness of samples collected and 
tested.
2.4 | Data analyses
To describe surveillance capacity during 2011-2017, we summarized 
the number of sentinel sites and rRT-PCR throughput capacity for 
laboratory testing by country. The collection of potential risk fac-
tors for SARI and in-hospital deaths were also noted. We estimated 
the relationship between annual rates of samples tested and posi-
tives by WHO transmission zone. We repeated this for each country 
during 7 years of surveillance using a generalized estimating equa-
tion method with repeated-measures Poisson regression where the 
dependent variables were counts of influenza-positive detections 
and samples tested for each year of the study and the independ-
ent variable WHO transmission zone.28 We explored the association 
between surveillance funding source and World Bank income clas-
sification status using Fisher's exact test to determine if there were 
non-random associations between income classification and fund-
ing source (eg CDC, WHO, or Government) as categorical variables. 
We also plotted the number of samples tested and the proportion 
of influenza detections among ILI and SARI case-patients during 
the 7-year surveillance period by age group to determine changes in 
the amount of testing by age group. We used a linear regression to 
identify potential trends in the number of influenza viruses shared 
with WHO CCs and samples reported to FluNet over time. Lastly, 
we used Mann-Whitney Rank Sum test to explore whether coun-
tries that used influenza vaccines in the private or public sector were 
more likely to report a greater number of influenza tests results to 
FluNet. Analyses were performed using SAS® 9.4 and StataCorp 
2019 Version 16.
4  |     IGBOH et al.
TA
B
LE
 1
 
C
ha
ra
ct
er
is
tic
s 
of
 th
e 
in
flu
en
za
 s
ur
ve
ill
an
ce
 s
ys
te
m
s 
in
 p
ar
tic
ip
at
in
g 
co
un
tr
ie
s 
20
11
-2
01
7
W
H
O
 
tr
an
sm
is
si
on
 
zo
ne
Co
un
tr
y
a  P
op
ul
at
io
n 
N
 (%
 
of
 A
fr
ic
a)
, 2
01
7
Ye
ar
 
su
rv
ei
lla
nc
e 
st
ar
te
d
W
H
O
-
de
si
gn
at
ed
 
N
at
io
na
l 
In
flu
en
za
 
Ce
nt
er
 2
01
7
d  E
Q
A
P 
(%
)
N
um
be
r o
f s
en
tin
el
 s
ite
s 
in
 2
01
7
Cu
m
ul
at
iv
e 
IL
I 
sp
ec
im
en
s t
es
te
d 
&
 %
 p
os
iti
ve
 fo
r 
in
flu
en
za
 n
/N
; (
%
)
Cu
m
ul
at
iv
e 
SA
RI
 
sp
ec
im
en
s t
es
te
d 
&
 %
 p
os
iti
ve
 fo
r 
in
flu
en
za
 (n
/N
; (
%
)
M
ea
n 
an
nu
al
 
sp
ec
im
en
s t
es
te
d 
&
 %
 p
os
iti
ve
 fo
r 
in
flu
en
za
 (n
/N
; (
%
)
In
flu
en
za
-
lik
e 
ill
ne
ss
Se
ve
re
 a
cu
te
 
re
sp
ira
to
ry
 
in
fe
ct
io
n
IL
I
SA
RI
IL
I &
 S
A
RI
N
or
th
er
n
A
lg
er
ia
b,
c  
41
 3
98
 1
98
 (9
)
20
11
Y
10
0
15
1
33
61
 (2
7)
10
96
 (3
5)
63
7 
(2
9)
So
ut
he
rn
So
ut
h 
A
fr
ic
ab
,c
,e
 
56
 7
17
 1
56
 (5
)
19
84
Y
89
3
8
99
67
 (9
)
27
 1
91
 (4
)
53
08
 (5
)
W
es
te
rn
C
ôt
e 
d'
Iv
oi
re
b,
c,
e  
24
 2
94
 7
50
 (2
)
20
07
Y
91
14
11
11
 0
48
 (1
0)
29
27
 (5
)
19
96
 (9
)
W
es
te
rn
D
em
oc
ra
tic
 
Re
pu
bl
ic
 o
f 
C
on
go
e  
81
 3
39
 9
88
 (8
)
20
08
N
92
11
9
87
34
 (6
)
57
55
 (5
)
20
70
 (6
)
W
es
te
rn
M
al
ie  
18
 5
41
 9
80
 (2
)
20
14
N
73
5
3
26
77
 (1
2)
49
6 
(8
)
45
3 
(1
1)
W
es
te
rn
N
ig
er
21
 4
77
 3
48
 (2
)
20
09
N
97
7
7
21
03
 (7
)
26
11
 (6
)
67
3 
(6
)
W
es
te
rn
N
ig
er
ia
e  
19
0 
88
6 
31
1 
(1
8)
20
09
N
99
4
4
79
15
 (7
)
16
27
 (4
)
13
63
 (6
)
W
es
te
rn
Se
ne
ga
l
15
 8
50
 5
67
 (1
)
19
96
Y
99
15
2
11
 7
15
 (1
3)
26
6 
(1
3)
17
20
 (1
3)
W
es
te
rn
To
go
e  
7 
79
7 
69
4 
(1
)
20
10
N
98
2
4
39
96
 (1
2)
55
6 
(8
)
65
0 
(1
2)
Ea
st
er
n
Ke
ny
ae
 
49
 6
99
 8
62
 (5
)
20
06
Y
98
7
7
24
76
 (9
)
17
 1
94
 (6
)
28
09
 (7
)
Ea
st
er
n
M
ad
ag
as
ca
rc
,e
 
25
 5
70
 8
95
 (2
)
19
78
Y
97
54
18
81
98
 (2
3)
17
71
 (1
7)
14
24
 (2
2)
Ea
st
er
n
M
al
aw
i
18
 6
22
 1
04
 (2
)
20
11
N
85
1
2
13
06
 (1
2)
54
15
 (7
)
96
0 
(8
)
Ea
st
er
n
M
oz
am
bi
qu
ee
 
29
 6
68
 8
34
 (3
)
20
13
N
96
1
2
15
5 
(1
4)
25
82
 (4
)
39
0 
(4
)
Ea
st
er
n
Ta
nz
an
ia
e  
57
 3
10
 0
19
 (5
)
20
08
Y
97
13
12
42
55
 (9
)
91
30
 (6
)
19
12
 (7
)
Ea
st
er
n
U
ga
nd
ae
 
42
 8
62
 9
58
 (4
)
20
07
Y
10
0
6
8
94
03
 (1
1)
77
05
 (8
)
24
44
 (9
)
Ea
st
er
n
Za
m
bi
ae
 
17
 0
94
 1
30
 (4
)
20
08
Y
99
2
4
46
43
(7
)
45
21
 (6
)
13
09
 (5
)
C
en
tr
al
 A
fr
ic
a
C
am
er
oo
nc
 
24
 0
53
 7
27
 (2
)
20
07
Y
97
24
3
83
47
 (1
6)
13
44
 (1
3)
13
84
 (1
5)
C
en
tr
al
 A
fr
ic
a
C
en
tr
al
 A
fr
ic
an
 
Re
pu
bl
ic
4 
65
9 
08
0 
(0
)
20
08
Y
-
7
1
71
69
 (4
)
0 
(–
)
10
24
 (4
)
To
ta
l
71
0 
75
1 
47
1 
(5
6)
19
78
-2
01
4
55
%
73
- 1
00
11
 (1
-5
4)
6 
(1
-1
8)
10
7 
52
0 
(1
1)
92
 1
81
 (8
)
28
 5
29
 (9
)
a D
at
a 
po
pu
la
te
d 
w
ith
 W
or
ld
 B
an
k 
20
17
 p
op
ul
at
io
n 
da
ta
. P
op
ul
at
io
n 
fo
r M
id
dl
e 
Ea
st
/N
or
th
 A
fr
ic
a 
us
ed
 a
s 
de
no
m
in
at
or
 fo
r A
lg
er
ia
. 
b I
nf
lu
en
za
 v
ac
ci
ne
 p
ol
ic
y 
or
 g
ui
de
lin
es
 a
va
ila
bl
e.
 
c S
ea
so
na
l I
nf
lu
en
za
 v
ac
ci
ne
 a
va
ila
bl
e 
in
 th
e 
pu
bl
ic
 s
ec
to
r. 
d E
xt
er
na
l Q
ua
lit
y 
A
ss
es
sm
en
t P
an
el
s 
(E
Q
A
P)
 d
at
a 
ar
e 
av
er
ag
ed
 fr
om
 2
01
1-
20
17
. 
e C
D
C-
fu
nd
ed
 c
ou
nt
rie
s.
 
     |  5IGBOH et al.
2.5 | Ethics and funding
This project was deemed a program evaluation and received a non-
research determination from the CDC IRB because it does not use 
data from human subjects; its primary intent was to determine the 
fitness and capacity of influenza surveillance to serve participating 
countries. The data collection forms and templates were reviewed 
and approved by the ANISE working group. Collaborating institu-
tions received official invitation letters requesting information about 
their surveillance systems. This project was supported by the ANISE 
executive committee and funded by CDC.
3  | RESULTS
3.1 | Characteristics of surveillance systems
Twenty-two (92%) of 24 ANISE members attended the 2018 annual 
meeting; 18 (81%) of these 22 agreed to participate in InSAFRO. 
These 18 countries have a cumulative population of 710 751 471 
which represents 56% of Africa's total population (Table 1). Four 
countries did not contribute data for analysis: two did not attend the 
2018 ANISE meeting and two were unable to complete the survey in 
time for analyses. On average, participating countries had conducted 
13 years of influenza surveillance (range: 5-41 years); South Africa 
and Madagascar had conducted surveillance the longest among the 
countries (ie, >30 years) (Figure 1).
InSAFRO countries collected influenza surveillance data through 
187 ILI and 104 SARI sentinel sites. On average, countries had 11 
(range: 1-54) ILI and 6 (range: 1-18) SARI sentinel sites. Ten (56%) of 
the 18 countries used the ILI and 14 (78%) used the SARI case defi-
nitions recommended by WHO.26 The eight countries that modified 
their ILI case definition and the four countries that modified their 
SARI case definition each identified cases with onset of fever 
within 7 days of illness onset rather than the WHO recommended 
10 days.26
On average, countries tested a cumulative 28 529 specimens a 
year (Table 1). The number of ILI samples decreased by 12% from 
16 210 in 2011 to 14 477 in 2017 while the number of SARI samples 
tested remained similar at approximately 14 000 specimens. Most 
(80%) of the 18 countries collected data about case-patients' age 
and preexisting medical conditions. More than half of the samples 
collected were from children aged <5 years (ie, 53%, 95% CI: 51-54 
from ILI and 61%, 95% CI: 57-65 from SARI). Few samples were 
from persons aged ≥65 years (1%, 95% CI: 1-2 from ILI and 3%, 95% 
CI: 3-3 from SARI). Only 10 (56%) of the 18 countries documented 
in-hospital outcomes (eg death, recovery, and transfers) for SARI 
case-patients.
InSAFRO countries spanned four WHO influenza transmission 
zones28; the Northern [Algeria] countries contributed a cumulative 
annual average of 636 specimens, the Western zone [Cote d'Ivoire, 
Democratic Republic of Congo, Mali, Niger, Nigeria, Senegal, Togo] 
8926 specimens, the Eastern zone [Kenya, Madagascar, Malawi, 
Mozambique, Tanzania, Uganda, Zambia] 11 248 specimens, the 
Central zone [Cameroon, Central African Republic] 2408 specimens, 
and the Southern zone [South Africa] zone 5308 (P ≤ .0001). Based 
on a Poisson regression model no evidence of a difference was 
seen in the rate of samples tested per million persons per year be-
tween transmission zones among surveyed countries: Central zone 
(4.7/1 000 000-y), Eastern zone (2.1/1 000 000-y), Northern zone 
(2.2/1 000 000-y), Southern zone (2.5/1 000 000-y) and Western 
zone (1.1/1 000 000-y, P ≤ .3).
Countries reported that influenza surveillance cost approx-
imately between $10 000 and $1 267 280 to operate each year 
F I G U R E  1   Countries participating 
in the influenza surveillance in Africa 
analysis
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(median $105 000). All 18 countries paid for surveillance with funds 
from multiple agencies (Figures 2 and 3). We found no associations 
between the type of external funding and World Bank income 
classification. Seven (39%) of the 18 countries conducted influenza 
surveillance as part of an integrated disease surveillance system for 
improved detection and response to leading causes of illness.
F I G U R E  2   Funding sources for influenza surveillance in Africa member countries, 2011–2017
F I G U R E  3   Funding trend in surveillance allocation from 2011 to 2017
     |  7IGBOH et al.
3.1.1 | Laboratory capacity
Countries tested a median of 1373 (interquartile range [IQR]: 745-
1975) specimens through rRT-PCR per year, of which on average 9% 
tested positive for influenza (range 7-41%). The proportion of sam-
ples tested for influenza was higher among ILI (mean 58%, range: 
54-60) versus SARI (42%, range 34-46) cases (P ≤ .002). All InSAFRO 
countries had rRT-PCR capacity for laboratory testing. All countries 
subtyped influenza A and nine (50%) gained the ability to lineage-
type influenza B during 2011-2017. Seventeen (94%) of the 18 
InSAFRO countries scored a mean of (95%, range: 88-98) on WHO 
external quality assurance panels 29 (Table 1). In 2011, there were 
eight National Influenza Centers (NIC) (44%) among the 18 coun-
tries; with Tanzania, Zambia, and Kenya subsequently gaining NIC 
status during the 2011-2017 (61%) period.
3.1.2 | Reporting & contribution to GISRS
During 2011-2017, the number of InSAFRO countries reporting to 
WHO FluNet increased from 15 (83%) to 17 (94%); all of which also 
had ≥4 consecutive years of year-round surveillance by the end of 
the survey period. On average, the surveyed countries reported a 
greater number of specimens (21%) on WHO FluNet than were re-
ported to our survey. Annually, InSAFRO countries also shipped in 
aggregate, an average of 728 influenza viruses to WHO CCs for virus 
characterization and strain selection for candidate vaccine viruses, a 
number which remained approximately the same during the study 
period.
While 11 (61%) of the 18 countries used influenza vaccines in 
the private sector and 5 (27%) in the public sector, only 3 (17%) had 
publicly available national guidelines or policies about the use of 
seasonal influenza vaccines. Seven (38%) had published or unpub-
lished estimates of the burden of respiratory illnesses attributable 
to influenza that could be used to explore the value proposition of 
influenza vaccines.4,15-17,20,21,30 During the study period, countries 
with influenza vaccines in the private sector reported an average 
of 27 797 samples to FluNet vs 13 202 among those without vac-
cines in the private sector (P < .0001); data about vaccine use in 
the private sector for Malawi and Mozambique were unavailable 
for this analysis.
4  | DISCUSSION
4.1 | Surveillance and laboratory capacity
Our results suggest that following substantial investment in capac-
ity-building at the turn of the millennium, most of the 18 African 
countries we evaluated sustained or strengthened influenza surveil-
lance and laboratory diagnostic capacity, routinely reported findings 
to WHO, and shared samples with WHO CCs. In 2012, Radin et. al 
reported a tenfold increase from 4623 specimens in 2006 to 44 763 
in 2010 among 15 African countries, 9 of which overlap with our 
survey countries.3 Our findings suggest most InSAFRO participants 
have continued to strengthen surveillance in the decade after the 
Radin report.
All surveyed countries had the capacity to test influenza 
specimens through rRT-PCR, which helped them to maintain sit-
uational awareness about respiratory viruses in their respective 
countries. Although the number of sentinel surveillance sites 
has not significantly increased from 2012, possibly in an effort 
to improve the cost-benefit of surveillance, there was an overall 
increase in sampling and testing. Sampling for SARI respiratory 
increased especially among children aged 0-4 years (Figure S2). 
The overall increase in SARI sampling, which was accompanied 
by a modest decrease in ILI sampling, might be attributed to an 
emphasis by the global community to strengthen severe respira-
tory illnesses surveillance to compensate for the perceived short-
comings of surveillance to track severe illnesses during the 2009 
pandemic.31,32
4.2 | Participation in GISRS and WHO CCs
Investment in surveillance capacity-building resulted in sustained 
reporting of virus activity to GISRS and shipment of specimens 
to WHO CCs, even after a 37% decrease in external funding for 
such activities. All countries contributed influenza viruses to one 
or more WHO CCs during the northern and southern hemisphere 
Vaccine Composition Meeting for vaccine candidate virus selection. 
Although specimen testing increased among participating countries, 
the number of positive viruses shared with WHO CCs by transmis-
sion zones remained similar throughout the study period (Figure S5). 
Although we suspect additional specimens were not requested by 
the CCs because of limitations in the number that CC's can charac-
terize. There may be value in setting benchmarks for the minimum 
and maximum number of influenza specimens collected within the 
beginning, middle, and end of epidemics that should be shipped 
quarterly to WHO CCs assuming year-round transmission. Such 
benchmarks might allow countries to ensure that they share timely 
specimens and maximize the chances that influenza viruses identi-
fied within their country will be adequately represented in vaccine 
formulations.
In addition to demonstrating sustained or increased testing 
capacity during 2011-2017, our survey showcases the increase in 
the number of NICs in Africa and their newly attained ability to lin-
eage-type influenza B. NICs are critical to the sustainability of sur-
veillance because they orchestrate laboratory surveillance within 
countries, provide support to subnational laboratories, and liaise 
with WHO and its CCs. NICs do proficiency testing for subnational 
laboratories, test clinical specimens for influenza, identify and fur-
ther characterize viruses, and report findings to WHO through 
FluMart. NICs also collect specimens for shipment to CCs either 
emergently, when they identify what might be novel viruses, or 
quarterly to inform vaccine strains selection. This is evident during 
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the current COVID-19 pandemic where NICs are the underpinning 
for the rollout of testing for SARs-CoV-2.23,24,33
In 2018, the WHO revised the Terms of Reference (TOR) for NIC 
status to exclude the requirements for national laboratories to iso-
late influenza viruses. This shift in TOR recognized that some CCs 
prefer that countries send influenza-positive specimens for rapid 
sequencing first rather than delay shipment with virus isolation at-
tempts. In Africa, virus isolation requirements frequently held back 
national laboratories from achieving WHO NIC designation; we an-
ticipate that more countries in Africa will now be able to attain WHO 
NIC designation because of the relaxed TOR.
4.3 | Funding and expansion of surveillance
Despite reduction in external contributions, influenza surveillance 
seemed sustainable during the past decade. Thirteen countries re-
ceived funds through US CDC cooperative agreements and indirect 
financial support from other partners (Figure 2). During 2010-2019 
two new countries were awarded capacity-building funds to es-
tablish their national surveillance programs by the US CDC, five 
moved from capacity-building cooperative agreements (on average 
450 000 USD during a 5-year period) to maintenance cooperative 
agreements (on average 250 000 USD) with a cumulative decrease 
in funding of 1 461 020.00 USD (37%). Two other countries moved 
to a sustainability cooperative agreement, and received on average 
50 000 USD, to support their established surveillance activities.
Despite notable national and institutional commitments, surveil-
lance systems in Africa still rely largely on external funding to sustain 
or increase surveillance capacity. All countries were also beneficia-
ries of the CDC-funded International Reagent Resource, which pro-
vided registered countries with the reagents for the surveillance of 
novel and emerging influenza strains at no cost. In addition, WHO, 
Institut Pasteur, and national governments supported influenza 
surveillance and regional capacity strengthening to respond to out-
breaks and for pandemic preparedness.
4.4 | Vaccines and policy
Seasonal influenza vaccines are available in African countries, how-
ever public sector access remains limited. Influenza vaccines were 
available in the private and public sector in two-thirds of the 18 sur-
veyed countries and, although more than a third had influenza dis-
ease burden estimates, less than one in five countries had publicly 
available national vaccine guidelines or policies. In countries using 
influenza vaccines, these were typically available in pediatric health 
centers, private pharmacies, and embassies except for two coun-
tries (South Africa and Madagascar) where influenza vaccines were 
licensed, offered routinely at the point of care, and recommended in 
the public sector. In South Africa, for example, free seasonal influ-
enza vaccines were available in all public primary care facilities with 
a limited stock of approximately 1 000 000 doses for use among 
persons at high risk of influenza complications. Of note, countries 
that used influenza vaccines in the private sector reported, on aver-
age, a higher number of samples to WHO FluNet.
Our survey suggests that a disproportionally high percent 
of specimens from InSAFRO countries came from children aged 
<5 years. Although 16% of the 2019 census population for coun-
tries is aged <5 years, children aged <5 years represented 61% of 
ILI and 53% of SARI specimens. Our finding is consistent with that 
of other studies in Africa including Zambia where 60-80% of SARI 
samples were from young children.21 The large percent of children 
which comprise surveillance case-patients might reflect underlying 
rates of severe respiratory illness among those in the extremes of 
age and health utilization patterns that focus scarce resource on 
children rather than older adults as noted in a handful of health uti-
lization surveys.17,20,21,30,34,35 Additional evaluations are needed to 
determine if the proportion of samples obtained from different age 
groups is representative of those who seek care at sentinel sites. 
Such evaluations might be useful because representative sampling 
was not included as a formal milestone for evaluation in CDC fund-
ing opportunity applications.
4.5 | Limitations
The InSAFRO analyses were limited to surveillance data from 18 out 
of 54 WHO Member States in Africa. Nevertheless, these 18 coun-
tries comprised half of Africa's population and our findings might be 
generalizable to additional countries in Africa. We did not compre-
hensively quantify external funding countries received for surveil-
lance. InSAFRO countries reported 21% more respiratory samples 
results to WHO FluNet than they reported to our survey, possibly 
because our survey allowed participants to report results once while 
FluNet allows countries to update backlogged results at any given 
time. We also did not enumerate the number of pediatric-focused 
health facilities in order quantify the proportion of specimens from 
clients aged <5 that were collected from pediatric inpatient or out-
patient health facilities. We did not explore exact amounts countries 
were awarded versus amounts spent in their cooperative agreement 
funds. Finally, our survey was not designed to explore how countries 
used surveillance findings for public health action.
5  | CONCLUSION
Our InSAFRO survey suggests that investments in capacity-building 
at the turn of the millennium led to sustainable influenza surveil-
lance among African countries. Despite substantial decreases in 
external funding, countries tested more respiratory samples, espe-
cially among children with SARI, and reported to FluNet more than 
ever before. InSAFRO countries have continued to share samples 
with WHO CCs and to meaningfully participate in GISRS. During 
the study period, several countries successfully achieved WHO NIC 
designation, and some gained the ability to lineage test influenza 
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B. These gains represent important achievements in seasonal and 
pandemic influenza preparedness. It will be important to continue to 
monitor capacity in the region and to observe if more countries use 
their gains in surveillance to strengthen vaccine programs and other 
respiratory virus mitigation and control measures.
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